Entwicklung einer serösen Retinopathie unter Behandlung eines metastasierten kutanen Melanoms

Translated title of the contribution: Development of serous retinopathy during therapy of a metastatic cutaneous melanoma

I. Lüdeke*, P. Terheyden, S. Grisanti, M. Lüke

*Corresponding author for this work
1 Citation (Scopus)

Abstract

Inhibitors of the mitogen-activated protein kinase (MAPK) signal pathway have decisively improved the prognosis of metastatic cutaneous melanoma in patients with an activating mutation in position V600 of the BRAF gene. We report on a patient who was regularly examined in our clinic while participating in a randomized blinded clinical trial. The aim of this trial was to examine the effectiveness and tolerability of a combination of the BRAF inhibitor dabrafenib and the MAPK kinase (MEK) inhibitor trametinib compared with a monotherapy with dabrafenib (plus placebo). During therapy the patient developed a diffuse neuroretinal detachment which could not be completely reversed after discontinuation of the study medication.

Translated title of the contributionDevelopment of serous retinopathy during therapy of a metastatic cutaneous melanoma
Original languageGerman
JournalOphthalmologe
Volume113
Issue number10
Pages (from-to)861-863
Number of pages3
ISSN0941-293X
DOIs
Publication statusPublished - 01.10.2016

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)

Fingerprint

Dive into the research topics of 'Development of serous retinopathy during therapy of a metastatic cutaneous melanoma'. Together they form a unique fingerprint.

Cite this